Merger Control in the Czech Republic (2026): Practical Timeline, Filing Tests & Documents for Private Equity Deals

Merger control czech republic obligations sit at the centre of nearly every private equity transaction that touches the Czech market in 2026, and getting them wrong is one of the most common causes of avoidable closing delay. As Czech deal volume rises, sponsors and their counsel face a heavier flow of notifications to the Office for the Protection of Competition (Úřad pro ochranu hospodářské soutěže, or ÚOHS) and a corresponding need to plan clearance into the transaction timetable from day one. This guide sets out the filing tests, the step-by-step procedure with responsible parties and realistic durations, the documents you must prepare, the fees to budget for, and the drafting points that keep a signed deal on track.

It is written for buy-side and sell-side counsel, in-house legal teams and deal project managers who need a working procedural playbook rather than high-level commentary.

Overview, what merger control covers in the Czech Republic

Merger control in the Czech Republic is the regime under which the competition regulator reviews concentrations, mergers, acquisitions of control, and the creation of full-function joint ventures, before they may be implemented, to prevent transactions that would substantially distort competition. For private equity buyers, the practical reality is that many portfolio acquisitions qualify as notifiable concentrations, and closing cannot lawfully proceed until clearance is granted. Understanding when a deal is caught, and building the review period into the transaction timetable, is therefore a core part of deal execution rather than an afterthought.

Private equity activity in the Czech market has strengthened into 2026, with more mid-market buyouts, bolt-on acquisitions and secondary transactions. The direct consequence is a larger number of merger filings and a heightened risk that deal teams underestimate the clearance clock. Sponsors running competitive processes or add-on strategies should assume that merger control czech republic analysis will be needed on a recurring basis and should standardise their approach accordingly.

What is merger control?

Merger control is a prior-authorisation system. The governing statute is Act No. 143/2001 Coll., on the Protection of Competition, which defines what counts as a concentration, sets the notification thresholds, establishes the review deadlines and empowers the regulator to prohibit, clear, or clear with conditions. A concentration typically arises where one undertaking acquires direct or indirect control over another, through the purchase of shares or assets, by contract, or by any other means that confer decisive influence. The concept of “control” is functional: it is about the ability to exercise decisive influence, not simply the size of a shareholding.

Who enforces it in the Czech Republic?

The regulator is ÚOHS, based in Brno. It receives notifications, runs the completeness and substantive assessment, requests further information, and issues clearance or prohibition decisions. Its decisions may be challenged internally (by way of an appeal to the chairman of ÚOHS) and subsequently before the administrative courts. For cross-border deals meeting EU turnover thresholds, jurisdiction shifts to the European Commission under the EU Merger Regulation, and the domestic filing is displaced, a point examined below.

Eligibility, filing tests and notification thresholds czech republic

The first task on any deal is to determine whether a filing is mandatory. This turns on two questions: is there a concentration (an acquisition of control or a qualifying merger or joint venture), and are the notification thresholds met? Both must be satisfied for a mandatory filing to arise. Where they are, notification is compulsory and closing is suspended until clearance, a suspensory obligation that private equity teams must respect.

Statutory thresholds (domestic tests)

Act No. 143/2001 Coll. sets turnover-based thresholds calculated by reference to the parties’ net turnover achieved in the Czech Republic, applied either on an aggregate basis for all undertakings concerned or by reference to a combination of aggregate and individual turnover figures. The tests are applied to the undertakings concerned, meaning, on the buy-side, the acquiring group as a whole (including all entities controlled by the same ultimate parent), not just the acquisition vehicle. Confirm the exact current threshold figures against the consolidated text of the Act before relying on them.

For private equity sponsors this is critical: turnover attributable to the fund’s other controlled portfolio companies may be aggregated with the target’s, which can bring an otherwise small acquisition above the threshold. Always run the turnover test on a group-wide basis and confirm which entities are controlled for turnover-attribution purposes before concluding that no filing is required.

EU vs Czech thresholds, when you must notify to the Commission

Where a transaction meets the worldwide and EU-wide turnover thresholds in Council Regulation (EC) No 139/2004 (the EU Merger Regulation, or EUMR), the European Commission has exclusive jurisdiction and a domestic Czech filing is not made. The EUMR operates a “one-stop shop”: a single Commission clearance covers the whole EU, including the Czech Republic. Deal teams must therefore test the EU thresholds first. If they are met, the filing goes to Brussels; if they are not, the Czech domestic test governs. Referral mechanisms exist in both directions, so cross-border deals should be scoped early to avoid parallel or misdirected filings.

PE nuances: control, joint control and creeping acquisitions

• Acquisition of portfolio companies. A buyout that transfers sole control of a target is a classic notifiable concentration where thresholds are met. Confirm control is genuinely acquired, some minority stakes carry veto or governance rights that confer control despite being below 50%.
• Joint control. Club deals, co-investments and consortium structures can create joint control by two or more sponsors. Joint control over a full-function entity is itself a concentration and must be assessed against the thresholds.
• Minority stakes with rights. A stake that confers decisive influence, through board nomination rights, veto powers over budget or strategy, or other governance controls, can trigger notification even where the equity percentage looks modest.
• Creeping acquisitions. Successive purchases from the same seller within a defined period may be treated as a single concentration for threshold purposes. Structure staged acquisitions with this aggregation rule in mind.

Step-by-step: from pre-deal to clearance

The following procedure sets out the merger filing czech process as a sequence of tasks, each with a primary owner and a realistic duration. Treat these steps as running in parallel with the wider deal timetable, and reflect the clearance period in the long-stop date.

1. Initial screening and urgency assessment (buy-side counsel). As soon as a target is identified, run the concentration and threshold analysis on a group-wide basis. Determine whether the filing is mandatory, whether EU or Czech jurisdiction applies, and whether any sectoral approvals run alongside. Flag mandatory filings immediately so the deal timetable accommodates suspensory review. A high-level screen can be done in 1–3 business days; a robust analysis with turnover attribution typically takes 1–2 weeks.
2. Pre-notification contact with ÚOHS (parties’ counsel + ÚOHS). For complex or borderline private equity deals, request an informal pre-notification contact. This lets the parties test the market definition, agree the factual focus and reduce the risk of a lengthy completeness back-and-forth. Request the contact by letter or email; expect it to be scheduled some weeks out, with preparation time beforehand.
3. Prepare the notification form and supporting bundle (lead counsel + local counsel). Draft the ÚOHS notification, assemble transaction documents, ownership charts, financials and market-share evidence. Coordinate buyer and seller inputs early, seller-side financial data is often the bottleneck. Standard deals take 1–3 weeks; complex private equity structures with overlapping portfolio holdings may take 4–6 weeks.
4. Filing mechanics and submission (filing party / counsel). Submit the completed, signed notification to ÚOHS with the full bundle and a power of attorney. The filing date is recorded by ÚOHS, but the statutory clock runs from when the notification is treated as complete. Confirm language requirements and that any required translations are attached.
5. Phase I review (ÚOHS). ÚOHS conducts an initial completeness check followed by a substantive assessment. The statutory Phase I period is 30 days, extendable on justified grounds. In practice, straightforward filings resolve within 1–2 months; incomplete filings or requests for further information will effectively pause or reset the clock.
6. Phase II investigation (ÚOHS investigators). If Phase I raises serious competition concerns, the case moves to an in-depth review. This is where remedies are negotiated. The extended statutory period is measured in months; complex contested cases can run several months in practice.
7. Clearance and closing coordination (ÚOHS decision; parties implement). A clearance decision, unconditional or with conditions, allows the parties to close once it becomes final. Where conditions or commitments apply, build in time to implement them and to satisfy any pre-closing undertakings.
8. Post-clearance monitoring (compliance monitor / parties). Where the decision imposes structural or behavioural commitments, a monitoring regime may apply for a period defined in the decision.

Required documents, checklist and drafting tips

A complete, well-organised bundle is the single biggest driver of a fast Phase I. Incomplete filings do not start the clock and generate follow-up requests that extend the review. The table below lists the core documents and who typically prepares each. Treat the preparation of financials and market-share evidence as the critical path, these usually depend on the seller and on management input.

Core documents (forms, transaction summary, ownership chart)

The notification, a clear description of the transaction, and an accurate ownership chart are the backbone of the filing. The ownership chart should show the buyer’s full controlled group, because that is the perimeter used for turnover attribution and for identifying overlaps with the target’s activities.

Financials and market-share evidence

Present turnover figures on the correct group-wide basis and explain your market definition transparently. Where there are horizontal overlaps or vertical relationships, provide market-share estimates with a clear methodology and cited sources. A defensible, well-reasoned market definition reduces the likelihood of an in-depth Phase II referral.

Confidential annexes and business secrets

ÚOHS accepts confidential annexes and requests for confidential treatment where there is a genuine justification. Provide a non-confidential version for the file and be prepared to submit unredacted documents for the regulator’s review on request. Flag business secrets clearly and consistently across the bundle.

Timeline & deadlines, practical expectations for PE deals

The statutory clock does not run continuously. It starts only when the notification is complete, and it is effectively suspended when ÚOHS issues a request for further information (a tolling event). This is why completeness at the point of filing matters so much: a bundle that triggers repeated information requests can turn a nominal 30-day Phase I into a multi-month exercise.

Statutory deadlines vs practical timelines

Plan against practical timelines, not just the statutory minimum. For a clean, unproblematic filing, budget one to two months to clearance. Where there are overlaps that require closer scrutiny, or where a Phase II is possible, budget several months and set the long-stop date accordingly. Building a realistic buffer into the SPA protects the deal from mechanical breach if review runs long.

Handling information requests (fastest practices)

Respond to information requests completely and quickly, partial responses invite further rounds and extend the tolling period. Nominate a single point of contact on the deal team to manage the ÚOHS relationship, keep a live information map so data can be produced on demand, and use the pre-notification stage to anticipate likely questions before the clock starts.

Costs and fees for merger control czech republic filings

Budget for two categories: the statutory filing (administrative) fee payable to ÚOHS, and the external advisory costs that scale with deal complexity. The statutory fee is generally modest relative to overall transaction costs, but the advisory spend, local counsel, economic analysis, translation, can be significant where markets overlap or the review becomes contentious. The figures below are estimates and should be treated as planning ranges, dated to 2026.

Statutory fees (ÚOHS)

The administrative filing fee is fixed by the applicable schedule of administrative fees. Because fee schedules can be updated, confirm the current 2026 figure against the applicable legislation and ÚOHS guidance before submitting, and account for it in the deal budget alongside advisory costs.

Typical advisor cost ranges for PE deals

Straightforward filings with no material overlap sit at the lower end of the counsel range. Where the deal creates horizontal overlaps that demand an economic study, add the cost of an economist and expect the overall spend, and the timeline, to rise. These ranges are estimates; obtain fixed or capped fee proposals at engagement.

What changes in 2026, regulatory and procedural updates to watch

Deal teams should monitor several developing themes in Czech and EU merger enforcement through 2026. Enforcement attention across Europe has sharpened in digital markets, healthcare and energy, and ÚOHS priorities tend to track those sectoral concerns. Expect closer scrutiny of transactions in concentrated local markets and of roll-up strategies that aggregate market power through successive small acquisitions, a structure common in private equity.

Industry observers also expect continued attention to jurisdictional allocation for borderline cross-border deals, and to the interaction between merger control and foreign-investment screening under the Czech FDI regime (Act No. 34/2021 Coll., on the Screening of Foreign Investments). Before relying on any threshold figure, fee, or procedural rule, verify it against the current ÚOHS guidance and the consolidated text of Act No. 143/2001 Coll., and check the official collection of laws (Sbírka zákonů) for any recent amendments. The safe planning assumption for 2026 is that review will be at least as rigorous as in prior years, so front-load your competition analysis.

Common pitfalls and PE drafting tips

Most clearance problems are self-inflicted and preventable. The recurring mistakes below cause the majority of avoidable delays in private equity merger filing workstreams.

• Late screening. Leaving the threshold analysis until after signing compresses the timetable and can force an unrealistic long-stop date. Screen at the outset.
• Turnover attribution errors. Testing thresholds on the acquisition vehicle alone, rather than the sponsor’s full controlled group, produces false negatives. Always aggregate group-wide.
• Incomplete information maps. A disorganised bundle triggers repeat information requests that toll the clock. Prepare a live information map early.
• Missing affiliate and portfolio data. Overlaps with existing portfolio companies are easy to miss and central to the substantive assessment.
• Inconsistent corporate approvals. Board resolutions and powers of attorney that do not match the filing party create authority and completeness problems.

On the drafting side, address antitrust clearance czech republic risk directly in the transaction documents. Make clearance an express condition precedent to closing, and calibrate the long-stop date against realistic, not statutory-minimum, timelines. Allocate the filing obligation and cooperation duties clearly, specify who bears the risk of remedies (a “hell or high water” or capped efforts standard), and consider a reverse break fee where the buyer’s portfolio creates the competition risk. Include information-sharing and gun-jumping safeguards so the parties do not integrate before clearance.

Next steps and practical checklist

A disciplined, front-loaded process is what keeps merger control czech republic obligations from derailing a closing. Use the following summary as your working checklist, and adapt the long-stop date and conditions in the SPA to reflect the realistic clearance timeline for your specific deal.

1. Screen the deal group-wide at the outset, confirm whether a concentration arises and whether Czech or EU thresholds are met.
2. Decide jurisdiction: domestic ÚOHS filing or EU Merger Regulation notification.
3. Request a pre-notification contact for complex or borderline deals.
4. Build the document bundle early, with financials and market-share evidence on the critical path.
5. File a complete notification so the statutory clock starts without delay.
6. Manage information requests through a single point of contact and a live information map.
7. Reflect clearance as a condition precedent and set a realistic long-stop date in the SPA.
8. Plan for possible remedies, monitoring and post-clearance compliance where overlaps exist.

For private equity teams planning Czech transactions in 2026, early competition analysis is the highest-return investment in deal certainty. Where a deal is likely to require notification, treat merger control as a parallel workstream from signing readiness onward, verify every threshold and fee against the current ÚOHS guidance and Act No. 143/2001 Coll., and coordinate the domestic and EU positions before you file. Doing so is the most reliable way to satisfy merger control czech republic requirements and to keep your closing on schedule. You can connect with a Czech private equity lawyer through the Global Law Experts network for deal-specific advice.

Sources

1. Úřad pro ochranu hospodářské soutěže (ÚOHS), main site
2. ÚOHS, Competition (English)
3. Act No. 143/2001 Coll., on the Protection of Competition
4. European Commission, Mergers
5. Council Regulation (EC) No 139/2004 (EU Merger Regulation)
6. Czech Bar Association (Česká advokátní komora)